Haug Partners LLP
- Financial, legal, consulting
We are seeking a strategic partnership for our client's patented Anti-Cancer Peptide technology for clinical development and commercialization.
The University of Graz, Austria (which partners with Inpharsearch AG of Switzerland on seeking commercialization) has developed a patented class of anti-cancer peptides (ACPs) with broad-spectrum efficacy. Engineered from innate immune system components, these peptides selectively target cancer cell membranes and induce cell death independent of the immune system. This novel mechanism enables both stand-alone and combination therapy applications for common, rare, and difficult to treat malignancies, including melanoma, glioblastoma, pancreatic, breast, and colon cancers.
Preclinical in vitro and in vivo studies demonstrated high specificity, strong selectivity, and low toxicity, with reduced risk of drug resistance. ACPs are compatible with scalable manufacturing via chemical or biosynthetic routes.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}